Journal
AIDS
Volume 36, Issue 11, Pages 1603-1605Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/QAD.0000000000003269
Keywords
-
Categories
Ask authors/readers for more resources
Enzalutamide, an androgen receptor inhibitor used for prostate cancer treatment, may interact with some antiretrovirals. However, this case report found no significant pharmacokinetic differences in the main antiretrovirals, dolutegravir and tenofovir, after the introduction of enzalutamide, even at higher doses.
Enzalutamide is an androgen receptor inhibitor used for the treatment of prostate cancer. Although enzalutamide causes a favorable adverse effect profile, it might cause drug-drug interactions with some antiretrovirals. No major differences on the main dolutegravir and tenofovir pharmokinetocs were observed in this case report when comparing baseline assessments with those following the introduction of enzalutamide, also when given at higher doses, in a 63-year-old male living with HIV and prostate cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available